stockrow
Friday 6 November 2026
Export BMRN’s income statement to Excel — free account
BioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.
- Revenue
- +32.0%
- EPS
- −296.6%
- Free cash flow
- −52.3%
- Total debt
- +599.5%
Quarter to September 2026, against a year earlier
55.89
0.23
−0.41%
Follow BMRN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
32.65 | 40.35 | 150.58 | 0.00 |
P/S ratio |
3.54 | 3.35 | 3.25 | 3.18 | |
P/FCF ratio |
15.90 | 14.32 | 15.27 | 21.33 | |
P/Operating CF |
114.39 | 49.28 | 65.84 | 61.71 | |
P/B ratio |
1.87 | 1.75 | 1.75 | 1.86 | |
Price to Tangible BV |
2.01 | 1.87 | 14.07 | 14.30 | |
EV/Sales |
3.39 | 3.26 | 4.22 | 4.12 | |
EV/EBITDA |
22.57 | 27.46 | 48.35 | 40.25 | |
EV/Operating CF |
13.20 | 12.10 | 16.78 | 22.25 | |
EV/FCF |
15.24 | 13.93 | 19.84 | 27.65 | |
Quick Ratio |
3.25 | 3.94 | 1.16 | 1.13 | |
Current Ratio |
5.21 | 5.81 | 2.39 | 2.44 | |
Net Debt/EBITDA |
33.25 | (5.44) | 15.85 | 71.05 | |
Debt/Assets |
7.86% | 16.65% | 35.71% | 36.08% | |
Debt/Equity |
0.10 | 0.23 | 0.66 | 0.67 | |
Asset Turnover |
0.44 | 0.41 | 0.36 | 0.38 | |
Operating CF/Net income |
(2.14) | 2.09 | 3.76 | (1.53) | |
Capex/Depreciation |
(2.76) | (1.31) | (0.35) | (0.22) | |
Interest Coverage |
(16.06) | 8.67 | 1.75 | (1.48) | |
Research and Development Expense of Revenue |
47.27% | 23.34% | 20.91% | 17.62% | |
Selling, General and Administrative Expense of Revenue |
51.02% | 33.71% | 39.97% | 32.56% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.47 | 0.47 | |
Share Based Compensation of Revenue |
5.36% | 5.67% | 7.65% | 5.22% | |
Graham Net Nets |
0.21 | 0.20 | (0.13) | (0.12) | |
Graham Number |
36.05 | 31.88 | 16.72 | 0.00 | |
Earnings Yield |
3.06% | 2.48% | 0.66% | (0.16%) | |
Free Cash Flow Yield |
6.29% | 6.98% | 6.55% | 4.69% | |
Revenue per Share |
4.56 | 3.98 | 5.12 | 5.29 | |
Operating CF per Share |
0.52 | 1.15 | 0.87 | 0.97 | |
Capex per Share |
(0.22) | (0.11) | (0.18) | (0.15) | |
Free Cash Flow per Share |
0.29 | 1.04 | 0.69 | 0.83 | |
Cash per Share |
8.14 | 11.55 | 4.52 | 3.80 | |
Shareholders Equity per Share |
31.74 | 32.27 | 32.68 | 32.32 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
31.74 | 32.27 | 32.68 | 32.32 | |
Free Cash Flow |
56.55 | 199.73 | 133.86 | 159.92 | |
Working Capital |
3,194.46 | 3,811.92 | 2,307.63 | 2,315.81 | |
Capital Expenditures |
(43.09) | (20.92) | (34.25) | (28.29) | |
Net Current Asset Value |
2,446.47 | 2,226.16 | (1,430.13) | (1,392.56) | |
EV/EBIT |
26.69 | 33.55 | 96.34 | 132.20 | |
Capex to Sales |
0.05 | 0.03 | 0.03 | 0.03 | |
Price to Operating Income |
27.84 | 34.50 | 74.15 | 102.01 | |
| Other line items | |||||
Average Receivables |
784.37 | 821.55 | 958.45 | 933.31 | |
Average Payables |
683.01 | 710.68 | 845.02 | 872.27 | |
Average Inventory |
1,265.77 | 1,274.03 | 1,561.35 | 1,589.12 | |
Average Assets |
7,291.48 | 7,869.01 | 9,589.89 | 9,592.05 | |
Average Common Equity |
5,872.49 | 6,002.78 | 6,174.40 | 6,156.37 |
Columns are period end dates · fundamentals updated 5 Nov 2026